• We have researched and studied the


    And the implications of plaques, neurofibrillary tangles, neuronal loss, and gliosis

    Discover Now
  • We are dedicated to the


    of medicines and committed to making a difference in healthy living

    Discover Now
  • We will


    on our research and efforts to fulfill the mission of the company

    Discover Now

Protecting the integrity of neurons in the brain to
maintain quality of life


NeuroTau, Inc. is a biotech company, formed in 2017, that focuses on developing drugs that target the disruption or decay of the important neurobiological protein called Tau, and other important and associated proteins like amyloid and processes to reduce harmful inflammation that can lead to many serious diseases with significant unmet medical needs.

Our development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Progressive Supranuclear Palsy, Frontotemporal Dementia, Alzheimer’s Disease, Traumatic Brain Injury, PTSD, Down’s syndrome, and Parkinson Disease.

On-going research has linked these diseases to various malfunctions of tau, amyloid and inflammation within the brain. By correcting them, NeuroTau aims at opening the way for a broad range of disease modifying mechanism-based therapies.

NeuroTau is led by a team of scientific, clinical and industry executives with over 75-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of brain-related diseases.

“People with tau diseases have a wide range of symptoms because basically, wherever tau is aggregating, those parts of the brain are degenerating” David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology at Washington University School of Medicine in St. Louis.


Our Company

NeuroTau was founded by a Scientist and Clinician who have collaborated for years on neurodegenerative disease. Through their combined vision, they have focused on developing drugs to address these conditions with an emphasis on tau.

Our Team


Neurodegenerative diseases are characterized by a loss of neuronal structure and function and can include the accumulations of proteins that will disrupt function which lead to a variety of neurodegenerative diseases such as PSP, CBD, AD, PD, DLB and others. It is likely that new therapies targeting upstream processes may alleviate the progression of many conditions like these.

Discover Now

Pharma Pipeline

NeuroTau has progressed its pipeline with therapies which are enabled to enter into the clinic as well as continuing preclinical studies on next generation assets with additional promise

View It


Our therapies are focused on helping people who suffer from serious neurodegenerative conditions like Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Down's Syndrome and Alzheimer’s Disease (AD)

Learn More


Information is available about those investing in NeuroTau and those wishing to invest in the company

Discover Now


Find the latest information about our company and our science

Check It

NeuroTau, Inc. is a biotech company, formed in 2017, that focuses on developing drugs that target the disruption or decay of the important neurobiological protein called Tau

Contact Us

Close Bitnami banner